Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986525 alone and with nivolumab in relapsed/refractory small cell lung cancer
2025-524090-16-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 2, open-label trial of BMS-986525 and nivolumab in small cell lung cancer (SCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Safety and tolerability. Planned start Jun 2026; status: authorised.
02
Drugs
BMS-986525nivolumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2025-524090-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524090-16-00.